KOD News and Press, Kodiak Sciences Inc From 12/23/19

Biotech, hands down, wins the race for out-performance in the healthcare sector. Delivering new, valuable medicines has proven to be a winning strategy, even if the growth in their stocks is based on the hope of future drugs. However, this list focuses on the top 10 healthcare stocks in 2019, n...

Christmas came early this year for anyone holding shares of these three biotech stocks. Each one produced eye-popping gains in 2019, but investors need to know if they can keep climbing in 2020 and beyond. Data source: Yahoo! Finance. While the short answer's "yes," there are some importa...

PALO ALTO, Calif. , Dec. 19, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Taiyin Yang, Ph.D., to ...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

PALO ALTO, Calif. , Dec. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the closing of its previously announced underwritten ...

Major benchmarks rebounded on Wednesday, lifted by new hope that a preliminary deal on trade between the U.S. and China might still be possible in the short run. Market participants also got some readings that made them more optimistic about the prospects for continued economic growth across the...

Gainers:  Protagonist Therapeutics (NASDAQ: PTGX ) +63% . More news on: Protagonist Therapeutics, Inc., Arbutus Biopharma Corporation, Kodiak Sciences Inc., Stocks on the move, Read more ...

Shares of Kodiak Sciences (NASDAQ: KOD) were jumping 17.3% higher as of 11:16 a.m. EST on Wednesday following the drugmaker's announcement after the market closed Tuesday of the specific pricing of a public stock offering. Kodiak plans to sell 6 million shares at a price of $46 per share -- ...

Schmitt Industries (NASDAQ: SMIT ) +13%  on $2M stock repurchase plan . More news on: Schmitt Industries, Inc., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Stocks on the move, Read more ...

Kodiak Sciences (NASDAQ: KOD ) has priced its public offering of 6M common shares at $46.00 per share, for expected gross proceeds of ~$276M. More news on: Kodiak Sciences Inc., Healthcare stocks news, Stocks on the move, Read more ...